NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a post-merger clinical-stage biopharmaceutical company that began trading publicly following its 2021 combination with Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners. The company is focused on developing therapies for critical and rare conditions, including its lead pipeline asset NRX-101, targeting suicidal bipolar depression, and aviptadil-based treatments for severe respiratory illness. NRX Pharmaceuticals filed an 8-K with the SEC on March 24, 2026, reporting a material corporate development. For comprehensive filing histories, SPAC transaction records, and sponsor data on NRXP and thousands of other vehicles, sign up for full access at SpacDesk.